Section Arrow
Quote
LCTX.NYSE-M
- Lineage Cell Therapeutics
Quotes are at least 15-min delayed:2025/05/29 20:30 EDT
Last
 --
-- (--)
Day High 
-- 
Prev. Close
0.6523 
1-M High
0.76 
Volume 
-- 
Bid
0.65
Ask
0.6555
Day Low
-- 
Open
-- 
1-M Low
0.425 
Market Cap 
148.96M 
Currency USD 
P/E -- 
%Yield -- 
10-SMA 0.52 
20-SMA 0.49 
50-SMA 0.47 
52-W High 1.15 
52-W Low 0.3651 
Exchange NYSE-M 
Valuation Estimation
EPS (Current/Estimated)
-0.07/-0.03
Enterprise Value
150.32M
Balance Sheet
Book Value Per Share
0.35
Cash Flow
Cash Flow Yield
--
Income Statement
Total Revenue
8.95M
Operating Revenue Per Share
0.05
Industry Comparison
More
Code Name   Last Change Change (%) P/E P/E Range
ALZNAlzamend Neuro Inc.5.44+2.12+63.86%-- 
ENTOEntero Therapeutics Inc.0.412+0.018+4.57%0.03PE
NCNANuCana plc0.037-0.0005-1.33%-- 
PLRZPolyrizon Ltd1.25+0.22+21.36%-- 
INABIN8bio0.1534+0.0114+8.03%-- 
Quotes are at least 15-min delayed：2025/05/29 20:30 EDT
Industry overview quotes are at least 15 minutes delayed
Business Description
Lineage Cell Therapeutics Inc is a clinical-stage biotechnology company focused on the development and commercialization of novel therapies for the treatment of degenerative diseases. The company's pipeline is based on two platform technologies including cell replacement and cell/drug delivery. Lineage Cell's product candidate is OpRegen, a retinal pigment epithelium transplant therapy for the treatment of dry age-related macular degeneration, OPC1, an oligodendrocyte progenitor cell therapy for acute spinal cord injuries, and VAC2, allogeneic cancer immunotherapy of antigen-presenting dendritic cells for non-small cell lung cancer, ANP1, an allogeneic auditory neuron progenitor cells transplant for hearing loss, and PNC1, an allogeneic photoreceptor cell transplant for vision loss.
Information provided by: etnet
Terms and Conditions
Bank of China (Hong Kong) Limited
Disclaimer:
This information is provided by ET Net Limited ("ET Net") and/or its third party information providers (the "Sources") and is strictly for reference only. It is not intended to provide any financial or professional advice and any person should not rely upon the same as such. You should obtain relevant and specific professional advice before making any investment decision. Before making an investment decision, you should consider, with the assistance of your professional securities adviser, whether the information is appropriate in light of your particular investment needs, objectives and financial circumstances. ET Net and the Sources endeavor to ensure the accuracy and reliability of the information provided. Notwithstanding the aforesaid, ET Net, the Sources and Bank of China (Hong Kong) Limited do not guarantee or make any representation, warranty or undertaking as to the accuracy, reliability, completeness or timeliness of this information, and accept no responsibility or liability whatsoever (whether in tort or contract or otherwise) for any loss or damage howsoever arising from or in reliance upon the whole or any part of such information.